SIRT or TACE in combination with lenvatinib and PD-(L)1 inhibitor in high-tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study
Jingjun Huang, Huimin Niu, Hui Zhang, Mingyue Cai, Zhiheng Wang, Yongjian Guo, Licong Liang, Liteng Lin, Tingqi Yang, Jiabai Huang, Yuchan Liang, Zhaoxiong Guo, Jingwen Zhou, Wensou Huang, Kangshun Zhu · 2026
Read SIRT or TACE in combination with lenvatinib and PD-(L)1 inhibitor in high-tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study by Jingjun Huang, Huimin Niu, Hui Zhang, Mingyue Cai, Zhiheng Wang, Yongjian Guo, Licong Liang, Liteng Lin, Tingqi Yang, Jiabai Huang, Yuchan Liang, Zhaoxiong Guo, Jingwen Zhou, Wensou Huang, Kangshun Zhu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13105518.txt.
Description
Jingjun Huang and fourteen co-authors compared in 2026 two liver-directed treatments for advanced liver cancer, each backed by the same drug pair. One route threads chemotherapy into the tumor's artery; the other delivers tiny radioactive beads instead. Both groups also took a targeted pill and an immune drug.
Records from four Chinese centers covered patients with heavy tumor burden, matched so the groups looked alike at the start. Survival without growth, overall survival, and tumor shrinkage were compared. The verdict helps doctors pick the stronger local weapon when cancer has spread through much of the liver.
Catalog record
| CREATOR | Jingjun Huang, Huimin Niu, Hui Zhang, Mingyue Cai, Zhiheng Wang, Yongjian Guo, Licong Liang, Liteng Lin, Tingqi Yang, Jiabai Huang, Yuchan Liang, Zhaoxiong Guo, Jingwen Zhou, Wensou Huang, Kangshun Zhu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |